ライフサイエンスコーパス: fluid retention

1 rt failure (HF), possibly because they cause fluid retention.

2 es appear not to contribute substantially to fluid retention.

3 r eGFR were associated with a higher risk of fluid retention.

4 n is particularly important in patients with fluid retention.

5 nship between zibotentan plasma exposure and fluid retention.

6 betes, although their use remains limited by fluid retention.

7 t, but still exhibited rosiglitazone-induced fluid retention.

8 al role of ENaC in thiazolidinedione-induced fluid retention.

9 congestive heart failure due to TZD-related fluid retention.

10 eriority in the management of RSG-associated fluid retention.

11 owever, their use is complicated by systemic fluid retention.

12 ansport in the CD that underlies TZD-induced fluid retention.

13 cites, and seven of eight showed evidence of fluid retention.

14 nly thrombocytopenia, leukopenia, fever, and fluid retention.

15 ents and insulin users developed TZD-related fluid retention.

16 betic, non-TZD users with chronic HF who had fluid retention.

17 compared between TZD users with and without fluid retention.

18 No patients were taken off study because of fluid retention.

19 he utility of this regimen is not limited by fluid retention.

20 of troglitazone, which could in theory cause fluid retention.

21 cities were asthenia, flu-like symptoms, and fluid retention.

22 moderate in severity, and likely related to fluid retention.

23 cates a post-pubertal hormonal imbalance and fluid retention.

24 cts, offers a promising strategy to mitigate fluid retention.

25 More macitentan-treated patients developed fluid retention (16 [23%] versus 10 [14%]) and cardiac a

26 Superficial edema (42% versus 15%) and fluid retention (45% versus 30%) were more prevalent wit

27 s include obesity, male sex, age, menopause, fluid retention, adenotonsillar hypertrophy, and smoking

28 We sought to define the characteristics of fluid retention after thiazolidinedione (TZD) initiation

29 Although fluid retention after treatment with TZD in diabetic pat

30 Fluid retention and anaemia adverse events, which have b

31 d anion secretion in pig jejunal tissue, and fluid retention and cGMP levels in STa-exposed loops.

32 PARgamma agonists, thiazolidinediones, cause fluid retention and edema due to unknown mechanisms.

33 Fluid retention and endothelial dysfunction have been re

34 ages with glycerol and electrolytes promotes fluid retention and fluid balance; however, more researc

35 Concerns about the increased risks of fluid retention and heart failure with ERA use have led

36 ignificantly attenuated side effects such as fluid retention and heart weight gain associated with PP

37 upplemental oxygen are indicated in cases of fluid retention and hypoxemia, respectively.

38 tients with cirrhosis who had no evidence of fluid retention and in 20 pair-matched healthy control s

39 in the renal medulla where inhibition causes fluid retention and increased blood pressure.

40 3 to 4 adverse events; the most common were fluid retention and infection.

41 cation of beverages that promote longer-term fluid retention and maintenance of fluid balance is of r

42 Fluid retention and redistribution result in systemic co

43 tic capillaries, leading to 2.5-fold greater fluid retention and severe lymphedema after inflammation

44 Fluid retention and shortness of breath are its cardinal

45 No direct association between the risk of fluid retention and the baseline degree of severity of H

46 zin treatment, baseline characteristics, and fluid retention and the relationship between zibotentan

47 antidiabetic activity while not causing the fluid retention and weight gain that are serious side ef

48 d receptor gamma (PPARgamma) that can induce fluid retention and weight gain through unclear mechanis

49 proteinemia is significantly correlated with fluid retention and weight gain, development of ARDS and

50 Fatigue, fluid retention, and excessive tearing became more commo

51 Fatigue, fluid retention, and eye tearing/conjunctivitis became m

52 including unintended weight loss, edema and fluid retention, and fat and muscle mass loss.

53 ain toxicities (> or = grade 2) were nausea, fluid retention, and fatigue, which occurred in 33%, 33%

54 alone decreased body weight, a surrogate for fluid retention, and further decreased albuminuria.

55 resistance is associated with inflammation, fluid retention, and hyperparathyroidism.

56 higher plasma potassium concentration, more fluid retention, and significantly lower FE(K) and FE(Na

57 caused fatigue, gastrointestinal complaints, fluid retention, and thrombocytopenia in a number of pat

58 Hypoproteinemia, fluid retention, and weight gain are associated with dev

59 Neutropenia and fluid retention are dose-limiting.

60 s to reduce blood pressure, body weight, and fluid retention as well as to improve renal function.

61 However, full activation of PPARy leads to fluid retention associated with edema and weight gain, w

62 Fluid retention associated with the use of TZD is common

63 Activation of this pathway mediates fluid retention associated with TZDs, and suggests amilo

64 In hemodialysis patients, greater fluid retention between 2 subsequent hemodialysis treatm

65 Such fluid retention can ultimately lead to pulmonary congest

66 tal complexity conveyed comparable shifts in fluid retention capacity within each chamber.

67 associated with significantly higher risk of fluid retention compared with dapagliflozin alone (zibot

68 the effects leading to increased adiposity, fluid retention, congestive heart failure, and bone frac

69 The higher risk of fluid retention could be attenuated by the combination o

70 decrease of at least 30% with no substantial fluid retention during the enrichment period (responders

71 and tolerability issues such as weight gain, fluid retention, edema, congestive heart failure, and bo

72 Fluid-retention events were observed in 33 (18%) of 179

73 to 424.5 mg/m2), 30 patients (81%) developed fluid retention, for which 11 (30%) subsequently stopped

74 ocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were mor

75 leak syndrome manifested by hypoalbuminemia, fluid retention, hypotension and, in one case, pulmonary

76 Current treatment of fluid retention in heart failure relies primarily on diu

77 Vasopressin mediates fluid retention in heart failure.

78 We tested the hypothesis that salt and fluid retention in heart-transplant recipients (HTRs) is

79 enhanced albuminuria reduction and mitigated fluid retention in patients with CKD.

80 scular disease and exclude treatment-related fluid retention in patients with HF and preserved/mildly

81 ntan, preserved kidney function with minimal fluid retention in patients with IgA nephropathy.

82 al egress of albumin with subsequent osmotic fluid retention in some, but not all eyes.

83 e volume, which were attributed to excessive fluid retention in the anterior prostate and to expansio

84 ne challenge testing revealed enhanced renal fluid retention in the DC ACT mice.

85 was performed to determine the incidence of fluid retention in this cohort.

86 The mechanisms by which fluid retention influences cardiovascular survival in he

87 Fluid retention is an important consideration in the use

88 reported that the PPARgamma agonist-induced fluid retention is independent of ENaC activity.

89 These findings indicate that fluid retention is partly engendered by a failure to ref

90 reduce albuminuria in diabetic nephropathy, fluid retention limits their use.

91 We evaluated correlations between changes in fluid retention markers and bioimpedance-measured extrac

92 understanding of the pathophysiology of the fluid retention may facilitate prevention.

93 Fluid retention, mediated largely by aldosterone excess,

94 as the earliest of the following: worsening fluid retention, new ascites, refractory arrhythmia, "fa

95 nase inhibition mediate, to some extent, the fluid retention observed in patients treated with mixed

96 Oedema or fluid retention occurred in 67 (27%) patients given daru

97 adverse event was mild-to-moderate oedema or fluid retention, occurring in 9%, 18%, and 2% for patien

98 rosis (31 [1%]), hypokalaemia (28 [1%]), and fluid retention or oedema (23 [1%]).

99 ents who required intensive care, had marked fluid retention, or were receiving intravenous vasodilat

100 heart rates, norepinephrine requirements and fluid retention (P </= .03).

101 ary leak syndrome, which is characterized by fluid retention, pulmonary edema, and kidney dysfunction

102 mong the imatinib quartile categories except fluid retention, rash, myalgia, and anemia, which were m

103 Fluid retention related to TZD tends to be peripheral an

104 alizations are related to sodium (Na(+)) and fluid retention resulting from neurohumoral up-regulatio

105 (ERAs) reduce albuminuria but are limited by fluid retention risk, particularly in patients with CKD.

106 In safety analyses, fluid retention, superficial edema, myalgia, vomiting, a

107 rimary end point was the incidence of severe fluid retention that necessitated treatment withdrawal.

108 , nausea, emesis, electrolyte imbalance, and fluid retention that were not dose limiting.

109 n of patients with recent volume overload to fluid retention, the magnitude of these benefits (even a

110 However, thiazolidinediones can cause fluid retention thereby increasing the risk of heart fai

111 These effects were related to improved fluid retention using PEG-BSA-24 as evidenced by the sig

112 RGZ/FFB prevented the fluid retention usually associated with RGZ (-1.6 vs. 5.

113 Fluid retention was an event of special interest, define

114 he management of rosiglitazone (RSG)-induced fluid retention was evaluated in a multicenter, randomiz

115 The risk of fluid retention was higher with higher zibotentan exposu

116 Similar fluid retention was measured in mice with endothelial-re

117 Fluid retention was not observed and cutaneous toxicity

118 Severe fluid retention was rare (4% of patients).

119 Fluid retention was reported by 19 of 169 patients (11.2

120 um channel ENaC in thiazolidinedione-induced fluid retention, we used mice with conditionally inactiv

121 unique benefits are shadowed by the risk for fluid retention, weight gain, bone loss and congestive h

122 Physical signs of fluid retention were compared between TZD users and an a

123 itentan run-in, patients who did not exhibit fluid retention were randomized to macitentan or placebo

124 Nineteen TZD users (17.1%) developed fluid retention, which reversed after drug withdrawal an

125 tentan were associated with a higher risk of fluid retention, which was attenuated with lower doses a

126 it lungs blocked sodium transport and caused fluid retention, which--together with patch-clamp and fl

127 However, OE2 may increase renal fluid retention within a physiological range of AVP.